AKBA
HEALTHCAREAkebia Therapeutics Inc
$1.48+0.03 (+2.07%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving AKBA Today?
No stock-specific AI insight has been generated for AKBA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.13$4.08
$1.48
Fundamentals
Market Cap$397M
P/E Ratio—
EPS$-0.02
Dividend Yield—
Dividend / Share—
ROE-5.5%
Profit Margin-0.0%
Debt / Equity—
Trading
Volume4.0M
Avg Volume (10D)—
Shares Outstanding268.3M
AKBA News
20 articles- Akebia (AKBA) Q1 2026 Earnings TranscriptMotley Fool·May 8, 2026
- Akebia Therapeutics Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 7, 2026
- Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline HighlightsYahoo Finance·May 7, 2026
- United Therapeutics (UTHR) Misses Q1 Earnings and Revenue EstimatesYahoo Finance·May 6, 2026
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 4, 2026
- Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of NephrologyYahoo Finance·May 4, 2026
- Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business HighlightsYahoo Finance·Apr 30, 2026
- Q32 Bio Gears Up to Report Q1 Earnings: What's in the Cards?Yahoo Finance·Apr 30, 2026
- Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·Apr 29, 2026
- Are Options Traders Betting on a Big Move in Akebia Therapeutics Stock?Yahoo Finance·Apr 28, 2026
- New Strong Sell Stocks for April 28thYahoo Finance·Apr 28, 2026
- Germany Anemia Treatment Market Forecast and Company Analysis Report 2026-2034 Featuring Akebia Therapeutics, GSK, Vertex, Pfizer, Sanofi, Takeda, Novartis, Johnson & Johnson, Roche, Biocon BiologicsYahoo Finance·Apr 24, 2026
- Akebia Therapeutics Leads The Pack Of 3 Promising Penny StocksYahoo Finance·Apr 13, 2026
- Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090Yahoo Finance·Apr 13, 2026
- Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation SymposiumYahoo Finance·Apr 7, 2026
- How The Akebia Therapeutics (AKBA) Narrative Is Shifting After Vafseo Revenue And Protocol UpdatesYahoo Finance·Apr 6, 2026
- Akebia Therapeutics R&D Day: Vafseo Growth Plan, Praliciguat Phase 2, New Kidney Pipeline TargetsMarketbeat·Apr 2, 2026
- Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of DirectorsYahoo Finance·Apr 1, 2026
- Guardian Pharmacy (GRDN) Soars 9.1%: Is Further Upside Left in the Stock?Yahoo Finance·Mar 31, 2026
All 20 articles loaded
Price Data
Open$1.52
Previous Close$1.45
Day High$1.54
Day Low$1.43
52 Week High$4.08
52 Week Low$1.13
52-Week Range
$1.13$4.08
$1.48
Fundamentals
Market Cap$397M
P/E Ratio—
EPS$-0.02
Dividend Yield—
Dividend / Share—
ROE-5.5%
Profit Margin-0.0%
Debt / Equity—
Trading
Volume4.0M
Avg Volume (10D)—
Shares Outstanding268.3M
About Akebia Therapeutics Inc
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—